Click on a filter below to refine your search. Remove a filter to broaden your search.
The Alzheimer’s disease-modifying drug donanemab is on track to be considered for full FDA approval by 2022, its developer said.
Big pharmaceutical companies are exploring “brand personality” in their marketing strategies, according to new research.